In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), with a price target of $25.00. The company's shares closed last Wednesday at $5.24, close to its 52-week low of $4.41. According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -26.1% and a 19.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Monopar Therapeutics Inc. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Actinium Pharmaceuticals with a $45.
https://www.tipranks.com/news/blurbs/maxim-group-thinks-actinium-pharmaceuticals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral